Phospho-S6 ribosomal protein: A potential new predictive sarcoma marker for targeted mTOR therapy

Modern Pathology

Volumn 21, Issue 3, 2008, Pages 231-237

  Iwenofu, O Hans ^a,b   Lackman, Richard D ^a   Staddon, Arthur P ^a   Goodwin, Diana G ^a   Haupt, Helen M ^a   Brooks, John S J ^a  

^a PENNSYLVANIA HOSPITAL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Immunohistochemistry; mTOR inhibitor; Phospho S6 ribosomal protein; Predictive marker; Sarcoma marker; Sarcoma therapy

Indexed keywords

AP 23573; DOXORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MULTICENTER STUDY; PRIORITY JOURNAL; SARCOMA; SCORING SYSTEM; TUMOR BIOPSY; TUMOR CLASSIFICATION; TUMOR RECURRENCE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADOLESCENT; ADULT; AGED; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROTEIN KINASES; RIBOSOMAL PROTEIN S6; SARCOMA; SIGNAL TRANSDUCTION; SIROLIMUS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 39749126103     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800995     Document Type: Article

References (27)

1. Longhi A, Errani C, De Paolis M, et al. Primary bone osteosarcoma: state of art. Cancer Treat Rev 2006;32:423-436.
2. Tibes R, Trent J, Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol 2005;45:357-384.
3. Cassier PA, Dufresne A, Fayette J, et al. Emerging drugs for the treatment of soft tissue sarcomas. Expert Opin Emerg Drugs 2007;12:139-153.
4. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056.
5. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;20:3586-3591.
6. Dufner A, Andjelkovic M, Burgering BM, et al. Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation. Mol Cell Bio 1999;19:4525-4534.
7. Tee AR, Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol 2004;16:29-37.
8. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol 2004;15:171-176.
9. Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-537.
10. Dennis PB, Fumagalli S, Thomas J. Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr Opin Genet Dev 1999;9:49-54.
11. Bjornsti M, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-348.
12. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 2004;16:564-575.
13. Dufner A, Thomas J. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 1999;253:100-109.
14. Ferrari S, Bandi HR, Hofsteenge J, et al. Mitogen-activated 70K S6 kinase. Identification of in vitro 40S ribosomal S6 phosphorylation sites. J Biol Chem 1991;266:22770-22775.
15. Sarbassov DD, Sabatini DM. Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J Biol Chem 2005;280:39505-39509.
16. Peng T, Golub TR, Sabatini DM. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol 2002;22:5575-5584.
17. Takano A, Usui I, Haruta T, et al. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol Cell Biol 2001;21:5050-5062.
18. Petroulakis E, Mamane Y, Bacquer OL, et al. mTOR: implications for cancer and anticancer therapy. Br J Cancer 2006;94:195-199.
19. Chawla SP, Tolcher AP, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas: update of phase II trial. J Clin Oncol 2007;25(June 20 Suppl):10076.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
21. Coindre JM, Terrier P, Guillou L, et al. Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 1986;58:306-309.
22. Vega F, Medeiros LJ, Atwell C, et al. Activation of mammalian target of rapamycin signaling pathway tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 2006;66:6589-6597.
23. El-Salem M, Raghunath PN, Marzec M, et al. Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders. Lab Invest 2007;87:29-39.
24. Castellvi J, Garcia A, Rojo F, et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006;107:1801-1811.
25. Aguirre D, Boya P, Bellet D, et al. Bcl-2 and CCND1/CDK4 as molecular markers of the cellular effects of mTOR inhibitors in human ovarian carcinoma cells. Apoptosis 2004;9:797-805.
26. Dilling MB, Germain GS, Dudkin L, et al. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 2002;277:13907- 13917.
27. Hosoi H, Dilling MB, Liu LN, et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 1998;54:815-824.